Combining capabilities to grow: Navitas acquires KAI Research

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/AndreyPopov)
(Image: Getty/AndreyPopov)

Related tags: Clinical trials, Clinical research, Clinical trial management, Fda, Nih, Cdc, Africa, North america

Navitas has acquired KAI Research to expand its trial site footprint in North America and Africa as well as bolster its ability to manage clinical trials in a number of research areas.

Based in the US, KAI will provide Navitas will its existing relationships with clinical sites as well and its network of service providers in the US and in Africa. According to a spokesperson for Navitas, KAI will continue to work with the US government through clinical research contracts in areas of emergent and epidemic infectious diseases with a priority on the African continent supported by partners and sites throughout Africa.

The spokesperson added that through this agreement Navitas’ ability to interact with KAI’s network will put the company in a “unique standpoint in serving federal agenices like the US Food and Drug Administration (FDA), National Institute of Health (NIH), Center for Disease Control (CDC), and Department of defense.”

Per the acquisition, Navitas will also obtain KAI’s e-clinical solutions and patient registries which will enable the company to expand its Phase II and III capabilities in North America and add to its offerings in Europe.

The spokesperson added, “The addition of KAI’s capabilities translates to global trial capabilities across North America, Europe and APAC markets.  Combining these operational and TA capabilities with our proprietary AI driven OneClincial platform allows us to be a great partner to small and mid-tier customers as well as to large pharma.”

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars